INS and polycystic ovary syndrome: While it has not been specifically shown to lower the risk of cardiovascular events in patients with PCOS, existing mechanistic and clinical evidence supports its use as a protective measure against the cardiovascular risks associated with insulin resistance and excess insulin [21].